Research & Trials > Studies To Participate In
|Study topic||Type||Start Date||End Date||Status||About the study:|
|-High dose Vitamin D supplementation in Stage 4 Colorectal cancer patients||Interventional||2015-?||Ongoing||
A large body of evidence suggests that high blood levels of Vitamin D decreases the risk of developing cancer, especially colorectal cancer. Very little is known about what role optimum blood levels of Vitamin D can play in the treatment of cancer. The purpose of this clinical trial is to study the therapeutic effect and the safety of high-dose vitamin D supplementation in stage 4 (metastatic) colorectal cancer patients.Who is eligible to participate?
Anyone who has a stage four colorectal cancer diagnosis, living in Ontario or British Columbia, may be eligible to participate. All participants need to have access to a Lifelabs facility for blood and urine collections.What is involved?
This 40 month study involves regular lab tests and follow up phone calls. Participation is fully voluntary and participants may withdraw at any time. Participants will be randomized into either a high-dose vitamin D treatment group or a control group. Participants in both groups may continue all other cancer treatments including chemotherapy.Treatment group
Participants in the treatment group receive daily oral high dose Vitamin D supplementation provided free of charge through the clinical study. They also receive daily calcium supplementation 1000mg daily as per guidelines, provided free through the clinical study. Participants will have monthly blood and urine tests for monitoring purposes. All laboratory tests are free of charge. Participants also need to be available for a 15 minute phone consultation with a study coordinator every 2 months.Control group
Participants in the control group will continue their usual amount of Vitamin D and/or calcium if they wish to do so. No supplements will be provided through the study. Participants will be asked to provide a small blood and urine sample at the beginning of the study, every 8 months and at the end of the study. These blood and urine tests will be free of charge.Contact person
If you have any further questions regarding this study or you are interested in participating in this study, please contact us:
|5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases||Interventional||2013-?||Ongoing||
Link to study
This is a prospective Phase II study.The purpose of this study is to monitor the side effects and treatment outcomes of delivering higher doses of radiation therapy to the tumour, while limiting the dose of radiation to the normal tissues. This will be done using a 5 day treatment schedule.
|Market Research Study||in-home or in-facility interview||2013-?||Ongoing||
Individuals diagnosed with Colorectal Cancer who would be willing to participate in a market research study on Colorectal Cancer
We are looking for individuals living in Toronto and Vancouver to take part in in-home or in-facility interview. You must have undergone treatment for your cancer and must have experience with one of the following cancer treatments:
A short telephone conversation will confirm whether you qualify. Qualified participants will be compensated.
If interested please call Antonella
|Cancer, Fertility and Motherhood||Online Survey||01 Jan 2012||Ongoing||
Every year, approximately 85,000 Canadian women are diagnosed with cancer; of these, over 4,000 women are between the reproductive age range of 20 and 39. Fertility and motherhood are important quality of life issues for young women with a history of cancer. However, very limited data are available to document how fertility matters are addressed when they receive cancer care in Canada.
This is a doctoral research study entitled, “Cancer, fertility and motherhood: Addressing the fertility needs of young women with cancer in times of stress, uncertainty, and time pressure”. The study aims to explore the retrospective views of female cancer survivors on fertility matters related to cancer care, and their perspectives on preserving fertility through assisted reproductive technologies.
The survey will take approximately 30 to 45 minutes to complete. Survey respondents can participate in a draw to win a $50 Amazon gift certificate.
|A Phase III Study of the Impact of a Physical Activity Program on Disease||Physical study||01 Jan 2012||Ongoing||
CO.21 – A Clinical Trial Studying the Benefit of a Structured Physical Activity Program for Men and Women Who Have Been Treated for Colon Cancer (CHALLENGE Trial)
A mission of the Colorectal Cancer Association of Canada is to support men and women living with this disease. Among the ways to carry out this mission is to provide information about what treatments are available to men and women diagnosed with colon cancer, including any clinical trials that test new treatment options or compare existing treatments to determine which is better.
We would like to tell you about CO.21, an international clinical trial led by Canada’s NCIC Clinical Trials Group, which is currently being conducted at many cancer centres across Canada and Australia. In addition to telling you about the CO.21 study, we would also like to dispel concerns that you might have about participating in a clinical trial.
Some studies have shown that being more physically active after your colon cancer diagnosis is associated with a lower risk of your colon cancer coming back. Several studies have also demonstrated that physical activity may improve other aspects, such as quality of life, physical fitness and fatigue for cancer survivors. However, few studies have focused on colon cancer survivors and larger, better controlled studies, like CO.21, are needed to see if this is true.
The CO.21 study is an exciting clinical trial that is currently enrolling patients who have completed their treatment for colon cancer, but who are not currently meeting the public health guidelines for recommended levels of leisure time physical activity. This study is being done because we do not know if a structured physical activity program designed to increase the physical activity you do in your free time will reduce the chance of the cancer coming back. We hope to learn how increasing physical activity influences colon cancer and the processes in your body which may play a role in the development of cancer. We also hope to learn more about how taking part in a physical activity program influences physical activity participation, physical fitness, quality of life and psychological well-being of people who have been diagnosed with and received treatment for colon cancer.
You will want to discuss the benefits and risks of participating in CO.21 with your oncologist or family doctor. Clinical trial research is highly regulated in Canada. As a participant in any clinical trial, you will always be fully informed of any risks; you must sign a consent form that explains the study and describes the risks and benefits. Of course, you may withdraw at any time from a clinical trial, if you wish. During the trial, you are closely monitored by a research team of doctors, nurses and other health-care professionals.
Many people also worry about being a “guinea pig’ and that you may get a placebo or care that is not as good as current best treatments. Clinical trials typically compare the current best treatment option to a new treatment option that researchers believe may be better than the current standard. Clinical trials are essential in developing new treatments, care, and prevention strategies for people with cancer. At present, for the type of participants involved in CO.21, there is usually no treatment provided following surgery and chemotherapy other than being monitored by a doctor. The purpose of the CO.21 study is to determine whether a structured physical activity program, in addition to receiving general health education materials, can prevent colon cancer from coming back.
We encourage you to find out more about CO.21 and other clinical trials to see whether they may offer other possible treatment options for you. For more information about clinical trials, CO.21, the NCIC Clinical Trials Group, and other clinical trials in Canada, you may wish to visit the following websites:
About CO.21: o CO.21 (NCIC CTG website) o CO.21 (ClinicalTrials.gov – an international clinical trials registry)
About cancer clinical trials: o Canadian Cancer Society o US National Cancer Institute
About other clinical trials in Canada: o Canadian Cancer Trials
About the NCIC Clinical Trials Group:
The NCIC Clinical Trials Group (NCIC CTG) is a cancer clinical trials cooperative group that conducts phase I-III trials testing anti-cancer and supportive therapies across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute, and is supported by the Canadian Cancer Society. The NCIC CTG’s Central Office is located at Queen’s University in Kingston, Ontario, Canada.
|Bayer Health Care Project||Interview||Ongoing||Ongoing||
Bayer HealthCare is currently recruiting stage II, III, and IV colorectal cancer patients and caregivers to
share the details of their cancer journey through a phone, audio or video interview. They are hoping
to reach as many Canadians as possible touched by colorectal cancer who are willing to share their
inspirational stories with others afflicted with the disease so that they may draw courage and strength
throughout their journey. The voice of the colorectal cancer patient is a valuable and riveting one and
you will be able to effectively communicate your unique perspective, providing hope and guidance
to families currently dealing with a diagnosis. Your time commitment is minimal but should you wish
to become more involved in this initiative, Bayer HealthCare will be happy to provide the details
surrounding additional activities.
The CCAC strongly encourages you to participate in this initiative. You would be bringing a voice to the colorectal cancer journey and your efforts will undoubtedly assist so many afflicted with this disease. Your time will be nicely rewarded with a gift card. Please consider participating by contacting Ethan Pigott ( firstname.lastname@example.org) at your earliest convenience. You each have such a compelling story to tell and it needs to be told and heard.
|Juravinsky Survivorship Project||Interview||Ongoing||Ongoing||
The CCAC is collaborating with the Juravinsky Cancer Centre on a survivorship project that has been long
overdue. Examining the needs and concerns of colorectal cancer survivors post treatment between 0-
5 years, 5-10 years and 10-20 years is certainly a worthy endeavour for the literature contains very little
in this respect, at least as it relates to >5 years survival. Colorectal cancer survivors have at one time or
another expressed concerns or unaddressed needs in respect of their post treatment cancer journey.
Here is how you can help with the collaboration:
Your efforts are very much appreciated and it is our hope that this survivorship project will somehow shape the manner in which colorectal cancer is managed and followed up. Please submit your replies to email@example.com .
|Self Care Catyalysts Study||Phone Interview||Ongoing||Ongoing||
We are interviewing 60-85 year-olds with colorectal cancer (pre- or post-surgery, or metastatic) about their personal experiences, health goals, and treatment decisions. The insights drawn from these interviews will be used to develop health solutions and programs that better meet patients’ needs. Your personal information will be kept strictly con? dential.
Participation involves a 45-minute to 1-hour phone interview followed by 5 days of short answer journal-writing (10 minutes per day). You will be ? nancially compensated for your time.
If you or anyone you know would be interested in participating, please contact (289) 936-9378 or firstname.lastname@example.org.
Who We Are: Self Care Catalysts is a health research, strategy, and solutions company with a unique concept and approach. We believe that patients deserve a strong voice within the health care industry and need to be active participants in their treatment choices. We work with members of the health care industry to ensure that they hear the patients’ voice and understand that patients’ needs go beyond the purely medical.
Why Participate: It’s a win-win scenario. Individuals become part of the team in treating their own health challenges – using their experiences to help both themselves and their peers – and the health care industry gains a more comprehensive understanding of patients and how to provide them with what they really want and need.
|The Lived Experience of Cancer Costs: Synthetic Antibodies in Relation to Distributive Justice||Focus Group||Ongoing||Ongoing||
We are Dr. Kerry Bowman and Mr. Alan Warner from Mount Sinai Hospital. Dr. Bowman is the principle investigator and Mr. Warner is the research coordinator for the Genome Canada sponsored research study called ‘The Lived Experience of Cancer Costs: Synthetic Antibodies in Relation to Distributive Justice’.
The central premise of Canadian health care advocates for equal and quality care for everyone. Equity in cancer care is of growing concern for Canadians due to sharply rising drug costs and the variation of drug coverage afforded by drug plans throughout the country.
Our research is based on a larger study for new cancer treatment known as synthetic (artificial) antibodies. Our aim will examine disease impact in our two target cancers groups - colorectal and ovarian -with particular attention to the burden of drug costs. To understand the lived experience of cancer costs for Canadians who have had ovarian or colorectal cancer we will explore broad demographic and psychosocial factors. For example we will look things such as costs in relation to employment status, insurance contracts and coverage, immigration status, urban or rural location prevalence, family member time off work – such as spouse, increased day care costs, travel and accommodation costs for treatment. This research will involve participation in one focus group, which will take about one hour each.
The information generated from this study will be used for improved planning and potential creation of more effective ways of distributing cancer treatments. Should you be interested, your participation would be strictly voluntary and greatly appreciated.
Principle Investigator: Dr. Kerry Bowman Assistant Professor Family and Community Medicine, University of Toronto Bioethicist Mount Sinai Hospital Tel: 416-586-4800 ext 2163 email@example.com
Research Coordinator: Mr. Alan Warner Research Coordinator Department of Bioethics, Mount Sinai Hospital Samuel Lunenfeld Research Institute Tel: 416-586-4800 ext 2163 firstname.lastname@example.org
|Market Research Study on Colorectal Cancer||Focus Group||February, 2013||Ongoing||
We are looking for individuals who have been diagnosed with Colorectal Cancer and caregivers to participate in a 2 hour focus group.
TParticipants will be compensated $100 for their time and contribution.
If you happen to know anyone that may be interested, please pass on this information!
If interested in participating, please contact us at: Toll free #: 1-877-714-0880, Local #: 604-714-5902 or email: email@example.com
Information gathered during the study will be treated confidentially and there will be no attempt to sell you anything. CRC Research is a member of the Market Research and Intelligence Association (Canada) and the Market Research Association (USA)
|Patients and caregivers needed for colorectal cancer interviews||Interview||Ongoing||Ongoing||
A leading pharmaceutical company is developing new medications for cancer
treatment. They are hoping to gain a better understanding of the experiences of patients
with advanced cancer. The feedback from these interviews will help them better
understand patients’ experience with advanced cancer and will help to educate and support
We are conducting 30 minute telephone interviews with patients and caregivers. The questions we will be asking will focus on:
Patient and caregiver input is essential to developing patient support programs. Participants will help identify key impacts associated with this disease. All feedback will be held in the strictest confidence and no unique identifiers will be used or attached to any participant.
We are looking for patients who are:
We appreciate you considering taking part. Your input is essential to providing the necessary guidance to the sponsor of this research study to move forward with patient treatment and education.
Please contact us by phone or email:
Olga Friedlander at:
or Ross Morrison at:
|Canadian Patients’ Views on Open Science in Biobanking||Online Survey||Ongoing||Ongoing||McGill University is conducting a very important study examining the opinions of patients from across Canada with respect to the new practice of “open science” in biobanks and genetic databases. They are attempting to determine how Canadians feel about the sharing of health information from tissue, blood and/or DNA samples between collaborating researchers around Canada. Many of you have provided these types of samples and would therefore be great candidates for the completion of the online survey.|
|Individuals diagnosed with Metastatic Colorectal Cancer who would be willing to participate in a market research study on Metastatic Colorectal Cancer||Market Research Study||Ongoing||Ongoing||
We are looking for individuals living in Toronto, Edmonton and Vancouver to take part in in-home interviews. You must have been diagnosed as KRAS wildtype, and may or may not currently be receiving treatment
A short telephone conversation will confirm whether or not you qualify. Qualified participants will be compensated for their time.
If interested please call:
1-877-747-0377 ext 224
|Aflibercept Safety and Quality of Life Program (ASQoP)||Market Research Study||Ongoing||Ongoing||
The ASQoP trial is designed to evaluate the safety and health-related quality of life of aflibercept
(Zaltrap®, Sanofi) in patients with metastatic colorectal cancer that were previously treated with an
oxaliplatin-containing regimen. Aflibercept is currently under review by Canadian authorities. It was
approved by the U.S. Food and Drug Administration (FDA) in August of 2012. This trial will provide
aflibercept to patients with metastatic colorectal cancer prior to its marketing authorization and/or
commercial availability in Canada. It will allow to document aflibercept overall safety and health-related
quality of life in the general patient population. This study has already started and saw its first patients
enrolled in 2012. Six Canadian sites from Alberta, Ontario and Quebec are involved into this worldwide
trial (16 countries, 900 patients).
More information on this trial is available at clinicaltrials.gov (NCT01571284): http://clinicaltrial.gov/ct2/show/NCT01571284